Fuji Pharma Co., Ltd.

Fuji Pharma Co., Ltd. is a pharmaceutical entity established in 1965, specializing in the development, manufacturing, and marketing of innovative drugs, generics, and biosimilars. The company maintains a strategic focus on women’s healthcare and acute medical care. Within the women’s healthcare sector, Fuji Pharma Co., Ltd. provides a portfolio of treatments for gynopathy, aiming to establish market leadership by supporting women’s health. Simultaneously, the firm’s acute medical care division emphasizes advancements in diagnostic imaging and oncology, leveraging specialized expertise to address critical clinical needs within the Japanese market.

Operational excellence is central to the company’s growth, underscored by the 2012 acquisition of OLIC (Thailand) Limited, a leading contract manufacturing organization. Fuji Pharma Co., Ltd. currently operates with 1,000-5,000 employees, managing production facilities including the Toyama Plant in Japan and the OLIC facility in Thailand. These sites are recognized for their technical capabilities in manufacturing complex injection and hormonal pharmaceutical products. By integrating these manufacturing assets, the company ensures high-quality output and supply chain resilience, supporting its mission to deliver essential medical solutions.

Publicly traded on the Tokyo Stock Exchange under the ticker TYO: 4554, Fuji Pharma Co., Ltd. continues to demonstrate robust market presence. The organization’s commitment to research and development, combined with its strategic manufacturing footprint, positions it as a key player in the pharmaceutical industry. Meet Fuji Pharma Co., Ltd.'s team to gain insight into the leadership driving these initiatives. With a focus on expanding its therapeutic reach, the company remains dedicated to improving patient outcomes through rigorous scientific innovationView more...